137 is the total number of securities Palo Alto Investors LP has owned. The longest Palo Alto Investors LP has owned a single stock is 45 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
BMRN | Biomarin Pharmaceutica... | 45 | 45 | 4.20% | 9.92% | 16.64% | Q2 2013 | Q2 2024 | 45 |
UTHR | UNITED THERAPEUTICS CO... | 45 | 45 | 4.35% | 9.59% | 15.29% | Q2 2013 | Q2 2024 | 45 |
INSM | INSMED INC | 45 | 45 | 0.38% | 7.42% | 16.61% | Q2 2013 | Q2 2024 | 45 |
STAA | STAAR Surgical Company | 45 | 45 | 0.97% | 5.04% | 11.83% | Q2 2013 | Q2 2024 | 45 |
FOLD | AMICUS THERAPEUTICS INC | 45 | 45 | 0.68% | 4.96% | 13.26% | Q2 2013 | Q2 2024 | 45 |
PRTA | PROTHENA CORP PLC | 45 | 45 | 0.14% | 2.79% | 9.14% | Q2 2013 | Q2 2024 | 45 |
VNDA | VANDA PHARMACEUTICALS INC | 43 | 43 | 0.11% | 2.84% | 5.78% | Q2 2013 | Q4 2023 | 43 |
CYTK | CYTOKINETICS INC | 43 | 43 | 0.03% | 0.19% | 0.88% | Q4 2013 | Q2 2024 | 43 |
ALGN | ALIGN TECHNOLOGY INC | 42 | 42 | 0.02% | 1.32% | 2.52% | Q1 2014 | Q2 2024 | 42 |
ABMD | ABIOMED INC | 38 | 38 | 4.13% | 10.13% | 17.12% | Q2 2013 | Q3 2022 | 38 |
KPTI | KARYOPHARM THERAPEUTIC... | 38 | 38 | 0.40% | 2.31% | 6.92% | Q1 2015 | Q2 2024 | 38 |
CLVS | CLOVIS ONCOLOGY INC | 36 | 36 | 0.42% | 5.17% | 14.55% | Q4 2013 | Q3 2022 | 36 |
RIGL | RIGEL PHARMACEUTICALS INC | 36 | 36 | 0.11% | 0.68% | 2.36% | Q2 2013 | Q1 2022 | 36 |
ACAD | ACADIA PHARMACEUTICALS... | 34 | 34 | 1.01% | 3.38% | 6.80% | Q1 2016 | Q2 2024 | 34 |
SAGE | SAGE THERAPEUTICS INC | 33 | 33 | 0.95% | 3.11% | 7.08% | Q2 2016 | Q2 2024 | 33 |
AMAG | AMAG PHARMACEUTICALS INC | 30 | 30 | 1.36% | 3.53% | 6.73% | Q2 2013 | Q3 2020 | 30 |
EPZM | EPIZYME INC | 29 | 29 | 0.06% | 3.28% | 8.32% | Q2 2015 | Q2 2022 | 29 |
MNTA | MOMENTA PHARMACEUTICAL... | 29 | 29 | 1.03% | 1.50% | 3.48% | Q2 2013 | Q2 2020 | 29 |
ALIM | ALIMERA SCIENCES INC | 28 | 28 | 0.07% | 0.58% | 2.37% | Q2 2013 | Q1 2020 | 28 |
DRNA | DICERNA PHARMACEUTICAL... | 26 | 26 | 0.03% | 0.28% | 1.04% | Q2 2015 | Q3 2021 | 26 |
ZGNX | ZOGENIX INC | 26 | 26 | 0.02% | 0.09% | 0.24% | Q3 2015 | Q4 2021 | 26 |
SPHS | SOPHIRIS BIO INC | 26 | 26 | 0.01% | 0.03% | 0.10% | Q3 2013 | Q4 2019 | 26 |
CELG | CELGENE CORP | 25 | 25 | 0.02% | 1.28% | 2.10% | Q3 2013 | Q3 2019 | 25 |
GILD | GILEAD SCIENCES INC | 24 | 24 | 0.01% | 0.99% | 2.16% | Q1 2014 | Q4 2019 | 24 |
EXAS | EXACT SCIENCES CORP | 24 | 24 | 0.20% | 0.72% | 1.81% | Q3 2013 | Q2 2019 | 24 |
RVNC | REVANCE THERAPEUTICS INC | 19 | 3 | 0.08% | 4.53% | 14.06% | Q1 2014 | Q2 2024 | 22 |
ALXN | ALEXION PHARMACEUTICAL... | 21 | 21 | 0.96% | 4.90% | 6.93% | Q2 2016 | Q2 2021 | 21 |
AIMT | AIMMUNE THERAPEUTICS INC | 21 | 21 | 0.04% | 1.91% | 6.23% | Q3 2015 | Q3 2020 | 21 |
ALDX | ALDEYRA THERAPEUTICS INC | 21 | 21 | 0.02% | 0.07% | 0.13% | Q2 2019 | Q2 2024 | 21 |
SHPG | SHIRE PLC | 20 | 20 | 0.01% | 1.08% | 1.66% | Q1 2014 | Q4 2018 | 20 |
HSGX | HISTOGENICS CORP | 19 | 19 | 0.00% | 0.07% | 0.29% | Q4 2014 | Q2 2019 | 19 |
WMGI | WRIGHT MEDICAL GROUP NV | 18 | 18 | 0.58% | 3.16% | 4.13% | Q4 2015 | Q1 2020 | 18 |
SNDX | SYNDAX PHARMACEUTICALS... | 18 | 18 | 0.06% | 0.71% | 1.33% | Q1 2020 | Q2 2024 | 18 |
SNSS | SUNESIS PHARMACEUTICAL... | 18 | 18 | 0.01% | 0.10% | 0.30% | Q3 2016 | Q4 2020 | 18 |
URGN | UROGEN PHARMA LTD | 18 | 18 | 0.02% | 0.03% | 0.05% | Q1 2020 | Q2 2024 | 18 |
GOSS | GOSSAMER BIO INC | 17 | 17 | 0.01% | 0.80% | 1.66% | Q2 2020 | Q2 2024 | 17 |
EHTH | EHEALTH INC | 16 | 16 | 0.61% | 2.03% | 4.39% | Q3 2020 | Q2 2024 | 16 |
ANAB | ANAPTYSBIO INC | 16 | 16 | 0.30% | 0.94% | 2.33% | Q3 2020 | Q2 2024 | 16 |
BIIB | BIOGEN INC | 15 | 15 | 3.01% | 7.12% | 9.27% | Q4 2020 | Q2 2024 | 15 |
ALKS | ALKERMES PLC | 15 | 15 | 0.16% | 1.19% | 1.60% | Q4 2020 | Q2 2024 | 15 |
TVTX | TRAVERE THERAPEUTICS INC | 15 | 15 | 0.09% | 0.23% | 0.35% | Q4 2020 | Q2 2024 | 15 |
IMMU | IMMUNOMEDICS INC | 14 | 14 | 1.24% | 5.98% | 22.65% | Q2 2017 | Q3 2020 | 14 |
KZR | KEZAR LIFE SCIENCES INC | 14 | 14 | 0.06% | 0.31% | 0.84% | Q2 2020 | Q3 2023 | 14 |
IDRA | IDERA PHARMACEUTICALS INC | 14 | 14 | 0.03% | 0.12% | 0.22% | Q1 2015 | Q2 2018 | 14 |
SQNM | SEQUENOM INC | 13 | 13 | 0.71% | 1.88% | 4.08% | Q2 2013 | Q2 2016 | 13 |
ARIA | ARIAD PHARMACEUTICALS INC | 13 | 13 | 0.63% | 1.31% | 2.30% | Q4 2013 | Q4 2016 | 13 |
ACRX | ACELRX PHARMACEUTICALS... | 13 | 13 | 0.10% | 0.34% | 0.84% | Q3 2014 | Q3 2017 | 13 |
KLDO | KALEIDO BIOSCIENCES INC | 13 | 13 | 0.04% | 0.33% | 0.52% | Q1 2019 | Q1 2022 | 13 |
MRNS | MARINUS PHARMACEUTICAL... | 8 | 5 | 0.01% | 0.02% | 0.02% | Q3 2015 | Q4 2020 | 13 |
IDRA | IDERA PHARMACEUTICALS INC | 13 | 13 | 0.01% | 0.01% | 0.03% | Q3 2018 | Q3 2021 | 13 |
ANAC | ANACOR PHARMACEUTICALS... | 12 | 12 | 1.07% | 6.36% | 14.60% | Q2 2013 | Q1 2016 | 12 |
PBYI | PUMA BIOTECHNOLOGY INC | 12 | 12 | 0.59% | 0.92% | 1.91% | Q4 2018 | Q3 2021 | 12 |
TCMD | TACTILE SYSTEMS TECHNO... | 12 | 12 | 0.02% | 0.05% | 0.08% | Q4 2020 | Q3 2023 | 12 |
ZLTQ | ZELTIQ AESTHETICS INC | 11 | 11 | 0.48% | 1.95% | 5.34% | Q3 2014 | Q1 2017 | 11 |
MIRM | MIRUM PHARMACEUTICALS INC | 11 | 11 | 0.07% | 0.14% | 0.26% | Q4 2021 | Q2 2024 | 11 |
ALIMERA SCIENCES INC | 11 | 11 | 0.04% | 0.07% | 0.11% | Q2 2020 | Q4 2022 | 11 | |
ADHD | ALCOBRA LTD | 11 | 11 | 0.01% | 0.05% | 0.09% | Q1 2015 | Q3 2017 | 11 |
KYTH | Kythera BioPharm CMN | 10 | 10 | 0.28% | 2.74% | 4.32% | Q2 2013 | Q3 2015 | 10 |
GRTS | GRITSTONE ONCOLOGY INC | 10 | 10 | 0.10% | 0.81% | 1.94% | Q1 2021 | Q2 2023 | 10 |
OREX | OREXIGEN THERAPEUTICS INC | 10 | 10 | 0.05% | 0.47% | 0.90% | Q1 2014 | Q2 2016 | 10 |
XOMA | Xoma Ltd. | 10 | 10 | 0.03% | 0.16% | 0.22% | Q2 2013 | Q3 2015 | 10 |
MGTA | MAGENTA THERAPEUTICS INC | 10 | 10 | 0.04% | 0.14% | 0.29% | Q2 2020 | Q3 2022 | 10 |
XON | INTREXON CORP | 10 | 10 | 0.04% | 0.08% | 0.12% | Q4 2014 | Q1 2017 | 10 |
NERV | MINERVA NEUROSCIENCES INC | 10 | 10 | 0.00% | 0.01% | 0.02% | Q2 2019 | Q3 2021 | 10 |
CYBX | CYBERONICS INC | 9 | 9 | 1.09% | 7.18% | 11.91% | Q2 2013 | Q2 2015 | 9 |
MDVN | MEDIVATION INC | 9 | 9 | 0.70% | 1.13% | 1.88% | Q2 2014 | Q2 2016 | 9 |
ALDR | ALDER BIOPHARMACEUTICA... | 9 | 9 | 0.03% | 1.09% | 2.34% | Q3 2017 | Q3 2019 | 9 |
CEMP | CEMPRA INC | 8 | 8 | 0.05% | 1.42% | 4.00% | Q4 2015 | Q3 2017 | 8 |
QLTI | QLT INC | 8 | 8 | 0.06% | 0.75% | 1.07% | Q2 2013 | Q1 2015 | 8 |
AUXL | AUXILIUM PHARMACEUTICA... | 7 | 7 | 5.59% | 8.95% | 10.88% | Q2 2013 | Q4 2014 | 7 |
CBST | CUBIST PHARMACEUTICALS... | 7 | 7 | 4.31% | 7.53% | 9.14% | Q2 2013 | Q4 2014 | 7 |
ENDP | ENDO INTL PLC | 7 | 7 | 1.09% | 2.33% | 3.82% | Q1 2015 | Q3 2016 | 7 |
AVEO | AVEO PHARMACEUTICALS INC | 7 | 7 | 0.03% | 0.36% | 1.04% | Q2 2013 | Q4 2014 | 7 |
HPTX | HYPERION THERAPEUTICS INC | 7 | 7 | 0.09% | 0.14% | 0.22% | Q2 2013 | Q4 2014 | 7 |
TRVN | TREVENA INC | 7 | 7 | 0.02% | 0.03% | 0.06% | Q1 2017 | Q3 2018 | 7 |
MARINUS PHARMACEUTICAL... | 7 | 7 | 0.01% | 0.02% | 0.03% | Q1 2021 | Q3 2022 | 7 | |
NVCR | NOVOCURE LTD | 6 | 6 | 0.16% | 1.00% | 1.94% | Q1 2023 | Q2 2024 | 6 |
HTWR | HEARTWARE INTL INC | 6 | 6 | 0.61% | 0.83% | 1.19% | Q1 2015 | Q2 2016 | 6 |
ISRG | INTUITIVE SURGICAL INC | 6 | 6 | 0.56% | 0.72% | 0.81% | Q2 2014 | Q3 2015 | 6 |
SNSS | SUNESIS PHARMACEUTICAL... | 6 | 6 | 0.07% | 0.23% | 0.35% | Q1 2015 | Q2 2016 | 6 |
RLMD | RELMADA THERAPEUTICS INC | 6 | 6 | 0.10% | 0.23% | 0.38% | Q1 2023 | Q2 2024 | 6 |
ATNX | ATHENEX INC | 6 | 6 | 0.06% | 0.12% | 0.18% | Q2 2020 | Q3 2021 | 6 |
BSTC | BIOSPECIFICS TECHNOLOG... | 6 | 6 | 0.02% | 0.08% | 0.12% | Q2 2014 | Q3 2015 | 6 |
ITMN | INTERMUNE INC | 5 | 5 | 2.02% | 8.43% | 16.88% | Q2 2013 | Q2 2014 | 5 |
QCOR | QUESTCOR PHARMACEUTICA... | 5 | 5 | 1.51% | 3.87% | 5.20% | Q2 2013 | Q2 2014 | 5 |
T107PS | WRIGHT MED GROUP INC | 5 | 5 | 1.88% | 2.44% | 3.22% | Q3 2014 | Q3 2015 | 5 |
SRPT | SAREPTA THERAPEUTICS INC | 5 | 5 | 0.87% | 2.06% | 3.69% | Q2 2023 | Q2 2024 | 5 |
P103PS | NPS PHARMACEUTICALS INC | 5 | 5 | 1.08% | 1.92% | 3.30% | Q4 2013 | Q4 2014 | 5 |
CLDN | CELLADON CORP | 5 | 5 | 1.14% | 1.46% | 1.75% | Q1 2014 | Q1 2015 | 5 |
NVRO | NEVRO CORP | 5 | 5 | 0.38% | 0.90% | 1.46% | Q2 2023 | Q2 2024 | 5 |
QURE | UNIQURE NV | 5 | 5 | 0.01% | 0.02% | 0.02% | Q3 2015 | Q3 2016 | 5 |
MLNT | MELINTA THERAPEUTICS INC | 5 | 5 | 0.00% | 0.01% | 0.03% | Q4 2017 | Q4 2018 | 5 |
THOR | THORATEC CORP | 4 | 4 | 0.51% | 2.92% | 5.26% | Q4 2014 | Q3 2015 | 4 |
SPPI | SPECTRUM PHARMACEUTICA... | 4 | 4 | 0.26% | 0.32% | 0.35% | Q2 2013 | Q1 2014 | 4 |
MNKKQ | MALLINCKRODT PUB LTD CO | 4 | 4 | 0.02% | 0.02% | 0.02% | Q3 2014 | Q2 2015 | 4 |
MLNTQ | MELINTA THERAPEUTICS INC | 4 | 4 | 0.00% | 0.00% | 0.00% | Q1 2019 | Q4 2019 | 4 |
VPHM | ViroPharma Incorporated | 3 | 3 | 1.35% | 9.17% | 13.42% | Q2 2013 | Q4 2013 | 3 |
IOVA | IOVANCE BIOTHERAPEUTIC... | 3 | 3 | 1.54% | 2.35% | 3.53% | Q4 2023 | Q2 2024 | 3 |
VERV | VERVE THERAPEUTICS INC | 3 | 3 | 0.33% | 0.64% | 0.86% | Q4 2023 | Q2 2024 | 3 |
BLUE | BLUEBIRD BIO INC | 3 | 3 | 0.41% | 0.53% | 0.66% | Q4 2023 | Q2 2024 | 3 |
PRVB | PROVENTION BIO INC | 3 | 3 | 0.14% | 0.42% | 0.78% | Q3 2022 | Q1 2023 | 3 |
GERN | GERON CORP | 3 | 3 | 0.09% | 0.19% | 0.30% | Q1 2014 | Q3 2014 | 3 |
TSHA | TAYSHA GENE THERAPIES INC | 3 | 3 | 0.08% | 0.19% | 0.26% | Q4 2023 | Q2 2024 | 3 |
VYNE THERAPEUTICS INC ... | 3 | 3 | 0.09% | 0.12% | 0.15% | Q4 2023 | Q2 2024 | 3 | |
APRE | APREA THERAPEUTICS INC | 3 | 3 | 0.03% | 0.10% | 0.16% | Q2 2020 | Q4 2020 | 3 |
RTRX | RETROPHIN INC | 3 | 3 | 0.06% | 0.09% | 0.16% | Q1 2020 | Q3 2020 | 3 |
NVAX | NOVAVAX INC | 3 | 3 | 0.06% | 0.08% | 0.11% | Q4 2021 | Q2 2022 | 3 |
ITCI | INTRA-CELLULAR THERAPI... | 3 | 3 | 0.05% | 0.06% | 0.07% | Q4 2019 | Q2 2020 | 3 |
NXTM | NXSTAGE MEDICAL INC | 2 | 1 | 0.02% | 0.05% | 0.07% | Q2 2013 | Q4 2014 | 3 |
SYRS | SYROS PHARMACEUTICALS INC | 3 | 3 | 0.02% | 0.03% | 0.03% | Q1 2021 | Q3 2021 | 3 |
VIRX | VIRACTA THERAPEUTICS INC | 3 | 3 | 0.02% | 0.02% | 0.02% | Q1 2021 | Q3 2021 | 3 |
ONXX | Onyx Pharmaceuticals, ... | 2 | 2 | 4.49% | 9.03% | 13.58% | Q2 2013 | Q3 2013 | 2 |
ALNY | ALNYLAM PHARMACEUTICAL... | 2 | 2 | 2.66% | 2.87% | 3.08% | Q4 2023 | Q1 2024 | 2 |
ACELYRIN INC | 2 | 2 | 0.88% | 1.09% | 1.31% | Q1 2024 | Q2 2024 | 2 | |
ELEV | ELEVATION ONCOLOGY INC | 2 | 2 | 0.56% | 0.67% | 0.78% | Q1 2024 | Q2 2024 | 2 |
SVNTQ | Savient Pharmaceutical... | 2 | 2 | 0.57% | 0.61% | 0.64% | Q2 2013 | Q3 2013 | 2 |
BIVV | BIOVERATIV INC | 2 | 2 | 0.51% | 0.56% | 0.61% | Q3 2017 | Q4 2017 | 2 |
AZN | ASTRAZENECA PLC-SPONS ADR | 2 | 2 | 0.11% | 0.42% | 0.73% | Q3 2021 | Q4 2021 | 2 |
NUVB | NUVATION BIO INC | 2 | 2 | 0.26% | 0.29% | 0.32% | Q1 2024 | Q2 2024 | 2 |
CYTK | Cytokinetics Inc. | 2 | 2 | 0.21% | 0.28% | 0.36% | Q2 2013 | Q3 2013 | 2 |
SLXP | SALIX PHARMACEUTICALS INC | 2 | 2 | 0.04% | 0.28% | 0.52% | Q4 2014 | Q1 2015 | 2 |
STOK | STOKE THERAPEUTICS INC | 2 | 2 | 0.19% | 0.19% | 0.20% | Q1 2024 | Q2 2024 | 2 |
HUM | HUMANA INC | 2 | 2 | 0.16% | 0.16% | 0.17% | Q1 2024 | Q2 2024 | 2 |
PEAK BIO INC | 2 | 2 | 0.03% | 0.10% | 0.17% | Q4 2022 | Q1 2023 | 2 | |
ACRS | ACLARIS THERAPEUTICS INC | 2 | 2 | 0.07% | 0.08% | 0.08% | Q1 2024 | Q2 2024 | 2 |
Align Technology, Inc. | 2 | 2 | 0.03% | 0.03% | 0.04% | Q3 2013 | Q4 2013 | 2 | |
SLNO | SOLENO THERAPEUTICS INC | 2 | 2 | 0.01% | 0.01% | 0.01% | Q2 2017 | Q3 2017 | 2 |
ALNYLAM PHARMACEUTICAL... | 1 | 1 | 5.16% | 5.16% | 5.16% | Q2 2024 | Q2 2024 | 1 | |
AGN | ALLERGAN INC | 1 | 1 | 0.93% | 0.93% | 0.93% | Q2 2014 | Q2 2014 | 1 |
AEGR | Aegerion Pharmaceutica... | 1 | 1 | 0.37% | 0.37% | 0.37% | Q2 2013 | Q2 2013 | 1 |
DNDNQ | Dendreon Corp | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2013 | Q2 2013 | 1 |
TCDA | TRICIDA INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q3 2020 | Q3 2020 | 1 |
SIGHT SCIENCES INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q4 2023 | Q4 2023 | 1 | |
EOLS | EVOLUS INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q3 2020 | Q3 2020 | 1 |
GBIO | GENERATION BIO CO | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2024 | Q2 2024 | 1 |
OREXQ | OREXIGEN THERAPEUTICS INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2016 | Q3 2016 | 1 |
CAPN | CAPNIA INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q1 2017 | Q1 2017 | 1 |
Download |
The securities at the top of the list , including Biomarin Pharmaceuticals, Inc, UNITED THERAPEUTICS CORP DEL, and INSMED INC, are the highest-conviction holdings of Palo Alto Investors LP.
The conviction is calculated by counting the number of quarters a security has been reported by Palo Alto Investors LP. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Palo Alto Investors LP owns currently or has owned in the past.